START
Status:Completed
Phase:IV
Principal Investigator(s):James D Neaton, PhD University of Minnesota - Clinical and Translational Science Institute
Objective:This study seeks to discover if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high, instead of waiting until the CD4+ count is at the level where there is good evidence for starting medicines. The START study also wants to learn more about how a strategy of starting HIV medicines early might affect other aspects of care, such as the chances of developing other illnesses or resistance to HIV medicines, the frequency of doctor visits, the cost of medical care, and general health and satisfaction.
Prevention Option(s):Treatment U=U
Study Design:Controlled, Randomized
Official Code:
Strategic Timing of Antiretroviral Treatment (START) (http://clinicaltrials.gov/ct2/show/NCT00867048)
Trial Sponsors:
University of Minnesota - Clinical and Translational Science Institute
Start Date
End Date
March 31, 2009
July 16, 2015
Enrollment:4,688
Age range:
18 Years ↔
any
Population:Cisgender Men, Cisgender Women, People Living with HIV